PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

Summary

Obesity and its adverse cardiometabolic consequences are major public health problems. Several features of obesity contribute to the associated cardiovascular risk and are potential targets for intervention. These include insulin resistance and beta cell dysfunction, reduced metabolic rate, and impaired aerobic capacity.The purpose of this study is to examine if the phosphodiesterase type 5A inhibitor tadalafil improves cardiometabolic health in individuals who are obese and insulin resistant.

Timeline

Start

2016-07

Primary completion

2020-06

Completion

2020-06

Drugs

Indications